Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sino Biopharmaceutical ( (HK:1177) ) has provided an update.
Sino Biopharmaceutical Limited announced that its new drug, TQ-B3234, a selective MEK1/2 inhibitor, has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation of China’s National Medical Products Administration. This inclusion is for the treatment of adult plexiform neurofibromas associated with neurofibromatosis type I, a condition with significant unmet medical needs in China. The drug has shown promising results in clinical trials, with high rates of tumor shrinkage and good tolerability, and its inclusion in the Breakthrough Therapy Designation process is expected to accelerate its launch, potentially benefiting more patients sooner.
The most recent analyst rating on (HK:1177) stock is a Hold with a HK$8.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a company incorporated in the Cayman Islands, focusing on the biopharmaceutical industry. It develops and markets pharmaceutical products, with a particular emphasis on innovative drugs and therapies.
Average Trading Volume: 159,264,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$139.5B
See more data about 1177 stock on TipRanks’ Stock Analysis page.